Member Rate applies for MassBio Member Company, Other State Bioscience Association Member Company, MassCONNECT Company, or Unemployed Individual
By registering for this course, you are eligible to receive a 10% discount applied to your registration of Business of Biotech 201. Contact firstname.lastname@example.org to obtain the coupon code to enter when checking out.
Business of Biotech 101 explores the business considerations that drive company strategies. Students will be provided with foundational information about the BioPharma industry and regulation via instruction, storytelling, and breakout group discussions. Industry ethics will be discussed, with emphasis on historical precedents. The course touches on topics such as market share, phases of development, patient population, and safety profile. A high-level overview of Research and Development, including pre-clinical through market approval will also reviewed.
- Tuesday, June 1st, 2021 12:30-3:00 PM EST
- Wednesday, June 2nd, 2021 12:30-3:00 PM EST
- Friday, June 4th, 2021 12:30-3:00 PM EST
Origins of the Biotech Industry: a Brief History
Addressing Unmet Medical Need
Biotechnology techniques used for therapeutics development
Business Models of the Sector and Industries within
Creating Barriers to Entry: Market Exclusivity
Early Stage Financing
Chief Executive Officer, Mellitus
John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies. As the first Entrepreneur-in-Residence with MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu. Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad. Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.